Literature DB >> 19157625

Angiogenesis in liver disease.

Mercedes Fernández1, David Semela, Jordi Bruix, Isabelle Colle, Massimo Pinzani, Jaume Bosch.   

Abstract

Angiogenesis and disruption of liver vascular architecture have been linked to progression to cirrhosis and liver cancer (HCC) in chronic liver diseases, which contributes both to increased hepatic vascular resistance and portal hypertension and to decreased hepatocyte perfusion. On the other hand, recent evidence shows that angiogenesis modulates the formation of portal-systemic collaterals and the increased splanchnic blood flow which are involved in the life threatening complications of cirrhosis. Finally, angiogenesis plays a key role in the growth of tumours, suggesting that interference with angiogenesis may prevent or delay the development of HCC. This review summarizes current knowledge on the molecular mechanisms of liver angiogenesis and on the consequences of angiogenesis in chronic liver disease. On the other hand, it presents the different strategies that have been used in experimental models to counteract excessive angiogenesis and its potential role in preventing transition to cirrhosis, development of portal hypertension and its consequences, and its application in the treatment of hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19157625     DOI: 10.1016/j.jhep.2008.12.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  171 in total

1.  Holeuryhalinity and its mechanisms in a cirriped crustacean, Balanus improvisus.

Authors:  H J Fyhn
Journal:  Comp Biochem Physiol A Comp Physiol       Date:  1976-01

Review 2.  Functional role of chemokines in liver disease models.

Authors:  Hacer Sahin; Christian Trautwein; Hermann E Wasmuth
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-26       Impact factor: 46.802

3.  Immortalized liver endothelial cells: a cell culture model for studies of motility and angiogenesis.

Authors:  Robert C Huebert; Kumaravelu Jagavelu; Ann F Liebl; Bing Q Huang; Patrick L Splinter; Nicholas F LaRusso; Raul A Urrutia; Vijay H Shah
Journal:  Lab Invest       Date:  2010-07-19       Impact factor: 5.662

Review 4.  Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice.

Authors:  Masatoshi Kudo
Journal:  Int J Clin Oncol       Date:  2010-05-28       Impact factor: 3.402

5.  Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma.

Authors:  Mathieu Bergé; Philippe Bonnin; Eric Sulpice; José Vilar; David Allanic; Jean-Sébastien Silvestre; Bernard I Lévy; Gordon C Tucker; Gérard Tobelem; Tatyana Merkulova-Rainon
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

6.  Effects of statins on the risk of hepatocellular carcinoma.

Authors:  Pejman G Mansourian; Masato Yoneda; M Krishna Rao; Fernando J Martinez; Emmanuel Thomas; Eugene R Schiff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-07

Review 7.  Antifibrotic therapies--emerging biomarkers as treatment end points.

Authors:  Jayant A Talwalkar
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

Review 8.  Bile acids regulate cardiovascular function.

Authors:  Sandeep Khurana; Jean-Pierre Raufman; Thomas L Pallone
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

9.  Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases.

Authors:  Claudia Paternostro; Ezio David; Erica Novo; Maurizio Parola
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

10.  Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats.

Authors:  Kuei-Chuan Lee; Wei-Fan Hsu; Yun-Cheng Hsieh; Che-Chang Chan; Ying-Ying Yang; Yi-Hsiang Huang; Ming-Chih Hou; Han-Chieh Lin
Journal:  Dig Dis Sci       Date:  2018-10-04       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.